Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993

被引:170
作者
Capewell, S [1 ]
Beaglehole, R
Seddon, M
McMurray, J
机构
[1] Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England
[2] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand
[3] Glasgow Western Infirm, Dept Cardiol, Glasgow G12 8RZ, Lanark, Scotland
关键词
coronary disease; mortality; drugs; risk factors; population;
D O I
10.1161/01.CIR.102.13.1511
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-We sought to determine how much of the recent, substantial fall in coronary heart disease (CHD) mortality rates in New Zealand can be attributed to "evidence-based" medical and surgical treatments and how much can be attributed to cardiovascular risk factor reductions. Methods and Results-A cell-based mortality model was developed and refined. This model combined (1) the published effectiveness of cardiological treatments and risk factor reductions with (2) data on all medical and surgical treatments administered to all CHD patients and (3) trends in population cardiovascular risk factors (principally smoking, cholesterol, and hypertension) from 1982 to 1993 in Auckland, New Zealand (population 996 000), Between 1982 and 1993, CHD mortality rates fell by 23.6%, with 671 fewer CHD deaths than expected from baseline mortality rates in 1982. Forty-six percent of this fall was attributed to treatments (acute myocardial infarction 12%, secondary prevention 12%, hypertension 7%, heart failure 6%, and angina 9%), and 54% was attributed to risk factor reductions (smoking 30%. cholesterol 12%, population blood pressure 8%, and other, unidentified factors 4%). These proportions remained relatively consistent after a robust sensitivity analysis. Conclusions-Approximately half the CHD mortality rate fall in Auckland, New Zealand, was attributed to medical therapies, and approximately half was attributed to reductions in major risk factors. These findings emphasize the importance of a comprehensive strategy that maximizes the population coverage of effective treatments and actively promotes a prevention program, particularly for smoking, diet, and blood pressure reduction.
引用
收藏
页码:1511 / 1516
页数:6
相关论文
共 41 条
  • [1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [2] INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS
    APPLEBY, P
    BAIGENT, C
    COLLINS, R
    FLATHER, M
    PARISH, S
    PETO, R
    BELL, P
    HALLS, H
    MEAD, G
    DIAZ, R
    PAOLASSO, E
    PAVIOTTI, C
    ROMERO, G
    CAMPBELL, T
    OROURKE, MF
    THOMPSON, P
    LESAFFRE, E
    VANDEWERF, F
    VERSTRAETE, M
    ARMSTRONG, PW
    CAIRNS, JA
    MORAN, C
    TURPIE, AG
    YUSUF, S
    GRANDE, P
    HEIKKILA, J
    KALA, R
    BASSAND, JP
    BOISSEL, JP
    BROCHIER, M
    LEIZOROVICZ, A
    BRUGGEMANN, T
    KARSCH, KR
    KASPER, W
    LAMMERTS, D
    NEUHAUS, KL
    MEYER, J
    SCHRODER, R
    VONESSEN, R
    SARAN, RK
    ARDISSINO, D
    BONADUCE, D
    BRUNELLI, C
    CERNIGLIARO, C
    FORESTI, A
    FRANZOSI, MG
    GUIDUCCI, D
    MAGGIONI, A
    MAGNANI, B
    MATTIOLI, G
    [J]. LANCET, 1994, 343 (8893) : 311 - 322
  • [3] MEDICAL-MANAGEMENT AND THE DECLINE IN MORTALITY FROM CORONARY HEART-DISEASE
    BEAGLEHOLE, R
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1986, 292 (6512): : 33 - 35
  • [4] BEAGLEHOLE R, 1995, AUCKLAND REGION CORO
  • [5] Bots M L, 1996, J Cardiovasc Risk, V3, P271, DOI 10.1097/00043798-199606000-00002
  • [6] Braunwald E, 1997, HEART DIS TXB CARDIO
  • [7] UNCERTAINTY IN THE ECONOMIC-EVALUATION OF HEALTH-CARE TECHNOLOGIES - THE ROLE OF SENSITIVITY ANALYSIS
    BRIGGS, A
    SCULPHER, M
    BUXTON, M
    [J]. HEALTH ECONOMICS, 1994, 3 (02) : 95 - 104
  • [8] Increasing the impact of cardiological treatments - How best to reduce deaths
    Capewell, S
    Pell, JP
    Morrison, C
    McMurray, J
    [J]. EUROPEAN HEART JOURNAL, 1999, 20 (19) : 1386 - 1392
  • [9] Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    Capewell, S
    Morrison, CE
    McMurray, JJ
    [J]. HEART, 1999, 81 (04) : 380 - 386
  • [10] Collins R, 1996, JAMA-J AM MED ASSOC, V276, P1873